تحميل
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
8.84 US$
+0.23 US$ · +2.67%
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
الإغلاق السابق
8.84 US$
+0.23 US$ · +2.67%
بعد ساعات التداول
8.84 US$
0.00 US$ · 0.00%
9 أكتوبر، 7:30 م ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
نطاق اليوم
السعر الحالي 8.84 US$
نطاق 52 أسبوعًا
السعر الحالي 8.84 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
47
قيمة عادلة
المشاعر
54
مختلط
المخاطر
47
مخاطر أعلى من المعتاد
الزخم
37
زخم متراجع
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
نطاق اليوم
السعر الحالي 8.84 US$
نطاق 52 أسبوعًا
السعر الحالي 8.84 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 9.68 مليون USD | 135.16 مليون USD | 91.37 مليون USD | 53.91 مليون USD | 200.58 مليون USD |
| تكلفة البضاعة المباعة | 3.7 مليون USD | — | — | — | — |
| الربح الإجمالي | 5.98 مليون USD | 135.16 مليون USD | 91.37 مليون USD | 53.91 مليون USD | 200.58 مليون USD |
| البحث والتطوير | 134.85 مليون USD | 222.52 مليون USD | 220.57 مليون USD | 135.56 مليون USD | 82.28 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 59.39 مليون USD | 67.2 مليون USD | 61.84 مليون USD | 49.9 مليون USD | 46.32 مليون USD |
| نفقات التشغيل | 190.54 مليون USD | 289.72 مليون USD | 282.41 مليون USD | 185.46 مليون USD | 128.6 مليون USD |
| دخل الفوائد | 14.14 مليون USD | 25.82 مليون USD | 31.01 مليون USD | 6.35 مليون USD | 42 ألف USD |
| الاستهلاك والإطفاء | 895 ألف USD | 893 ألف USD | 928 ألف USD | 744 ألف USD | 1.12 مليون USD |
| الدخل التشغيلي | −184.56 مليون USD | −154.56 مليون USD | −191.04 مليون USD | −131.56 مليون USD | 71.98 مليون USD |
| صافي الدخل | −244.09 مليون USD | −122.31 مليون USD | −147.03 مليون USD | −116.95 مليون USD | 66.98 مليون USD |
تم تحديث حقائق الشركة 10 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
صناديق متداولة تفصح عن تعرضها لهذا السهم.
iShares Russell 2000 ETFIWM9.81 مليون0.01%78.27 مليار USD0.19%278.94 US$+0.49%
State Street SPDR S&P Biotech ETFXBI8.08 مليون0.08%9.87 مليار USD0.35%153.77 US$+3.00%
Vanguard Extended Market ETFVXF4.58 مليون0.00%95.4 مليار USD0.05%235 US$+0.80%
Dimensional - US Small Cap ETFDFAS3.17 مليون0.01%33.87 مليار USD0.31%78.35 US$+0.32%
iShares Biotechnology ETFIBB2.99 مليون0.03%10.28 مليار USD0.44%206.49 US$+3.00%
Vanguard Russell 2000 ETFVTWO2.39 مليون0.01%18 مليار USD0.06%112.66 US$+0.50%
iShares Russell 2000 Growth ETFIWO2.01 مليون0.01%13.97 مليار USD0.24%356.78 US$+0.94%
Schwab U.S. Small-Cap ETFSCHA1.85 مليون0.01%21.73 مليار USD0.03%32.79 US$+0.40%iShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
